Sirtex Medical Names Matt Schmidt as CEO

March 25, 2024—Sirtex Medical announced the appointment of Matt Schmidt as Chief Executive Officer and Board of Directors member.

According to the company, Schmidt joined Sirtex as Executive Vice President of Global Sales in February 2023. In August, he was named Chief Commercial Officer.

Schmidt has 20 years of industry experience. He previously held leadership positions at Abbott Vascular, including divisional vice president, where he led the company’s United States coronary interventional cardiology device business. Before that, he was divisional vice president and general manager for Abbott’s vascular business in Japan.

He earned a bachelor’s degree in accounting from Goshen College in Goshen, Indiana, and an MBA from the University of Michigan in Ann Arbor, Michigan.

“I am optimistic about the future and honored to lead the Sirtex team during this exciting time in company history, especially given some of the transformative solutions we have brought to market over the last year,” commented Schmidt in the company’s press release. “We are a patient-centered organization with talented employees who are dedicated to improving lives. I am very much looking forward to what we will achieve together.”

The press release noted that Sirtex is a developer of minimally invasive cancer and embolization therapies. Its current lead product is SIR-Spheres Y-90 resin microspheres for targeted radiation therapy for liver cancer. In October 2023, the company announced the commercial availability of the Lava liquid embolic system, which is approved for treating peripheral vascular hemorrhage.